Portfolio company
Neogene Therapeutics
Country not known yet
Raised
Not known yet
Latest stage
Not known yet
Rounds recorded
Not known yet
Backed by
3 investors
Sectors
About
This biotechnology company develops engineered T cell receptor therapies targeting neoantigens in solid cancers for patients with oncology needs.
SourceFunding history · 0
No rounds recorded yet. The agent looks for them over time.
Similar companies
3T Biosciences
The company develops T-cell receptor therapeutics and target identification technologies for oncology patients to treat solid tumours.
PanCancerT
This biotech company develops T-cell receptor therapies for patients with solid tumours, focusing on targets like triple-negative breast cancer and melanoma.
Neobe
The company develops engineered microbial biotherapeutics designed to disrupt the microenvironment of solid tumours for cancer patients receiving immunotherapy.
OverT
This biotechnology company develops engineered cell therapies for the treatment of solid tumours in cancer patients.
Nectin Therapeutics
This company develops novel immunotherapeutic antibodies and antibody-drug conjugates for patients with solid and haematological cancers.
T-Therapeutics
The company develops T cell receptor therapeutics and bispecific engagers for patients with cancer and autoimmune diseases.
Exogene
This biotechnology company develops artificial intelligence and screening platforms to discover T-cell receptor-based cell therapies for oncology researchers and pharmaceutical developers.
CARGO Therapeutics
This biotechnology company develops engineered cell therapies to treat cancer patients with relapsed or resistant lymphoma.